Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared a post on LinkedIn:
“Turning intracellular kinases into druggable surface targets.
- Trafficking switch: Src flips to the surface via autophagolysosomal exocytosis.
- Active outside: eSrc phosphorylates extracellular proteins (e.g., ADAM17) – tumor growth.
- Tumor-selective: present on cancer cells, absent on normal cells.
- Class effect: other lipid-anchored proteins (Lyn, Hck) also exposed.
- Therapeutic angle: enables antibody targeting (TCE, ADC, radioligand) of a ‘non-druggable’ kinase.”
Title: Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer
Authors: Corleone S. Delaveris, Rita P. Loudermilk, Apurva Pandey, Soumya G. Remesh, Trenton M. Peters-Clarke, Snehal D. Ganjave, William J. N. Dougherty, Henry M. Delavan, Chunyue Wang, Jesse Ling, Juan Antonio Camara Serrano, Fernando Salangsang, Chien-Kuang Cornelia Ding, Nancy Greenland, Carissa E. Chu, Sima Porten, Veronica Steri, Jonathan Chou, Michael J. Evans, Kevin K. Leung, and James A. Wells
Read The Full Article
Other articles featuring Jean-Charles Soria on OncoDaily.